Trade-offs between drug toxicity and benefit in the multi-antibiotic resistance system underlie optimal growth of E. coli
暂无分享,去创建一个
[1] R. Kishony,et al. Antibiotic interactions that select against resistance , 2007, Nature.
[2] J. Rosner. Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Fralick. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli , 1996, Journal of bacteriology.
[4] S. Levy. Active efflux, a common mechanism for biocide and antibiotic resistance , 2002, Journal of applied microbiology.
[5] S. Levy,et al. Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway , 1993, Journal of bacteriology.
[6] G. Sethi,et al. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. , 2010, Biochimica et biophysica acta.
[7] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[8] P. Pomposiello,et al. The mar Regulon , 2005 .
[9] H. Mori,et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection , 2006, Molecular systems biology.
[10] H. Nikaido,et al. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants , 1996, Journal of bacteriology.
[11] S. Levy,et al. Active efflux mechanisms for antimicrobial resistance , 1992, Antimicrobial Agents and Chemotherapy.
[12] Remy Chait,et al. Correction: Optimal Drug Synergy in Antimicrobial Treatments , 2010, PLoS Computational Biology.
[13] S. Levy,et al. Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli , 1996, Antimicrobial agents and chemotherapy.
[14] R. Kishony,et al. Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.
[15] S. Levy,et al. Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon , 1997, Antimicrobial agents and chemotherapy.
[16] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[17] Michael E. Wall,et al. Model of Transcriptional Activation by MarA in Escherichia coli , 2009, PLoS Comput. Biol..
[18] Remy Chait,et al. Optimal Drug Synergy in Antimicrobial Treatments , 2010, PLoS Comput. Biol..
[19] D. Hooper,et al. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction , 1989, Antimicrobial Agents and Chemotherapy.
[20] J. Molnár,et al. Inducement and Reversal of Tetracycline Resistance in Escherichia coli K-12 and Expression of Proton Gradient-Dependent Multidrug Efflux Pump Genes , 2005, Antimicrobial Agents and Chemotherapy.
[21] A. M. George,et al. Active efflux of chloramphenicol in susceptible Escherichia coli strains and in multiple-antibiotic-resistant (Mar) mutants , 1994, Antimicrobial Agents and Chemotherapy.
[22] C. I. Bliss. THE CALCULATION OF MICROBIAL ASSAYS , 1956 .
[23] J. Gustafson,et al. The effects of salicylate on bacteria. , 2000, The international journal of biochemistry & cell biology.
[24] A. M. George,et al. Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline , 1983, Journal of bacteriology.
[25] S. Loewe. The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.
[26] D. A. Golden,et al. Transcription analysis of stx1, marA, and eaeA genes in Escherichia coli O157:H7 treated with sodium benzoate. , 2008, Journal of food protection.
[28] P. Sorger,et al. Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.
[29] D. Hartl,et al. Accelerated evolution of resistance in multidrug environments , 2008, Proceedings of the National Academy of Sciences.
[30] P. Venkatesan,et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.
[31] S. Levy,et al. The mar regulon: multiple resistance to antibiotics and other toxic chemicals. , 1999, Trends in microbiology.
[32] H. Bujard,et al. Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. , 1997, Nucleic acids research.
[33] R. Kishony,et al. A Differential Drug Screen for Compounds That Select Against Antibiotic Resistance , 2010, PloS one.
[34] Remy Chait,et al. Drug interactions modulate the potential for evolution of resistance , 2008, Proceedings of the National Academy of Sciences.
[35] P. Cluzel,et al. Dynamical determinants of drug-inducible gene expression in a single bacterium. , 2006, Biophysical journal.
[36] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[37] J. Vila,et al. Enhanced active efflux, repression of porin synthesis and development of Mar phenotype by diazepam in two enterobacteria strains. , 2004, Journal of medical microbiology.
[38] S. Levy,et al. marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli , 1988, Journal of bacteriology.
[39] D. Hooper,et al. Endogenous active efflux of norfloxacin in susceptible Escherichia coli , 1988, Antimicrobial Agents and Chemotherapy.
[40] B. Seaton,et al. The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 Å resolution , 2001, Nature Structural Biology.